Neoplasma Vol.70, No.3, p. 458–467, 2023
|
Title: What is the best time for postoperative radiation therapy in pN1 prostate cancer? |
Author: Francesco Alessandro Mistretta, Stefano Luzzago, Giulia Marvaso, Giulia Corrao, Ilaria Sabatini, Matteo Fontana, Federico Mastroleo, Mattia Zaffaroni, Maria Giulia Vincini, Ettore Di Trapani, Gabriele Cozzi, Roberto Bianchi, Matteo Ferro, Ottavio de Cobelli, Barbara Alicja Jereczek-Fossa |
|
Abstract: We retrospectively compared long-term biochemical recurrence rates (BCR) in pN1 PCa patients that underwent adjuvant radiotherapy (aRT) vs. no aRT/early salvage (esRT) after robot-assisted radical prostatectomy and extended pelvic lymphadenectomy. All PCa pN1 M0 patients treated at a single high-volume center between 2010 and 2020 were analyzed. Patients with 10 positive LNs, or persistently detectable PSA after RARP were excluded. Kaplan-Meier (KM) plots depicted BCR rates. Multivariable Cox regression models (MCRMs) focused on predictors of BCR. The cumulative incidence plot depicted BCR rates after propensity score (PS) matching (ratio 1:1). 220 pN1 patients were enrolled, 133 (60.4%) treated with aRT and 87 (39.6%) with no-aRT/esRT. aRT patients were older, with higher rates of postoperative ISUP grade group 4-5, and higher rates of pT3b stage. The actuarial BCR was similar (aRT 39.8% vs. no-aRT/esRT 40.2%; p=1). Median time to BCR was 62 vs. 38 months in aRT vs. no-aRT/esRT patients (p=0.001). In MCRMs, patients managed with no-aRT/esRT were associated with higher rates of BCR over time (hazard ratio [HR]: 3.27, p
|
|
Keywords: prostate cancer; radiation therapy; prostatectomy; adjuvant radiotherapy; early salvage radiotherapy; biochemical recurrence |
|
Published online: 25-Jul-2023
|
Year: 2023, Volume: 70, Issue: 3 |
Page From: 458, Page To: 467 |
doi:10.4149/neo_2023_230403N182
|
|
download file |
|
|
|
|